Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2015 Nov 7

PMID 26543328

Citations 32

Authors

Gregor Hoermann

Georg Greiner

Peter Valent

Affiliations

Soon will be listed here.

Abstract

The term myeloproliferative neoplasms (MPN) refers to a heterogeneous group of diseases including not only polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), but also chronic myeloid leukemia (CML), and systemic mastocytosis (SM). Despite the clinical and biological differences between these diseases, common pathophysiological mechanisms have been identified in MPN. First, aberrant tyrosine kinase signaling due to somatic mutations in certain driver genes is common to these MPN. Second, alterations of the bone marrow microenvironment are found in all MPN types and have been implicated in the pathogenesis of the diseases. Finally, elevated levels of proinflammatory and microenvironment-regulating cytokines are commonly found in all MPN-variants. In this paper, we review the effects of MPN-related oncogenes on cytokine expression and release and describe common as well as distinct pathogenetic mechanisms underlying microenvironmental changes in various MPN. Furthermore, targeting of the microenvironment in MPN is discussed. Such novel therapies may enhance the efficacy and may overcome resistance to established tyrosine kinase inhibitor treatment in these patients. Nevertheless, additional basic studies on the complex interplay of neoplastic and stromal cells are required in order to optimize targeting strategies and to translate these concepts into clinical application.

Citing Articles

Myeloproliferative Neoplasms and Cardiovascular Disease: A Review.

Leiva O, Liu O, Zhou S, How J, Lee M, Hobbs G Curr Treat Options Oncol. 2024; 25(10):1257-1267.

PMID: 39278999 DOI: 10.1007/s11864-024-01255-8.

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.

Haage T, Charakopoulos E, Bhuria V, Baldauf C, Korthals M, Handschuh J J Hematol Oncol. 2024; 17(1):43.

PMID: 38853260 PMC: 11163796. DOI: 10.1186/s13045-024-01562-5.

Exploring the molecular mechanisms between lymphoma and myelofibrosis.

Wang J, Li Y Am J Transl Res. 2024; 16(3):730-737.

PMID: 38586105 PMC: 10994807. DOI: 10.62347/NWJO7078.

The impact of gut microbial signals on hematopoietic stem cells and the bone marrow microenvironment.

Liu X, Zhang H, Shi G, Zheng X, Chang J, Lin Q Front Immunol. 2024; 15:1338178.

PMID: 38415259 PMC: 10896826. DOI: 10.3389/fimmu.2024.1338178.

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.

Hasselbalch H, Junker P, Skov V, Kjaer L, Knudsen T, Larsen M Cancers (Basel). 2023; 15(17).

PMID: 37686599 PMC: 10486581. DOI: 10.3390/cancers15174323.

References

Miyazono K . Tumour promoting functions of TGF-β in CML-initiating cells. J Biochem. 2012; 152(5):383-5. DOI: 10.1093/jb/mvs106. View

Ni H, Barosi G, Hoffman R . Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol. 2006; 126(2):241-7. DOI: 10.1309/4YGK-ED5L-WFW4-AVDV. View

Okayama Y, Kawakami T . Development, migration, and survival of mast cells. Immunol Res. 2006; 34(2):97-115. PMC: 1490026. DOI: 10.1385/IR:34:2:97. View

Di Raimondo F, Palumbo G, Molica S, Giustolisi R . Angiogenesis in chronic myeloproliferative diseases. Acta Haematol. 2002; 106(4):177-83. DOI: 10.1159/000046614. View

Gabillot-Carre M, Lepelletier Y, Humbert M, de Sepuvelda P, Ben Hamouda N, Zappulla J . Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood. 2006; 108(3):1065-72. DOI: 10.1182/blood-2005-06-2433. View

Levine R, Gilliland D . Myeloproliferative disorders. Blood. 2008; 112(6):2190-8. PMC: 2962533. DOI: 10.1182/blood-2008-03-077966. View

Griffin J, Leung J, Bruner R, Caligiuri M, Briesewitz R . Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003; 100(13):7830-5. PMC: 164673. DOI: 10.1073/pnas.0932698100. View

Medinger M, Passweg J . Role of tumour angiogenesis in haematological malignancies. Swiss Med Wkly. 2014; 144:w14050. DOI: 10.4414/smw.2014.14050. View

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

10.

Mayerhofer M, Valent P, Sperr W, Griffin J, Sillaber C . BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002; 100(10):3767-75. DOI: 10.1182/blood-2002-01-0109. View

11.

Selvan R, Butterfield J, Krangel M . Expression of multiple chemokine genes by a human mast cell leukemia. J Biol Chem. 1994; 269(19):13893-8. View

12.

Rosti V, Massa M, Vannucchi A, Bergamaschi G, Campanelli R, Pecci A . The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007; 38(3):280-6. DOI: 10.1016/j.bcmd.2007.01.003. View

13.

de Klein A, Van Kessel A, Grosveld G, Bartram C, Hagemeijer A, BOOTSMA D . A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982; 300(5894):765-7. DOI: 10.1038/300765a0. View

14.

Duhrsen U, Martinez T, Vohwinkel G, Ergun S, Sun L, McMahon G . Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow. Growth Factors. 2001; 19(1):1-17. DOI: 10.3109/08977190109001072. View

15.

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

16.

Castro-Malaspina H, Jhanwar S . Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res. 1984; 154:307-22. View

17.

Verstovsek S, Kantarjian H, Mesa R, Pardanani A, Cortes-Franco J, Thomas D . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12):1117-27. PMC: 5187954. DOI: 10.1056/NEJMoa1002028. View

18.

Mayerhofer M, Aichberger K, Florian S, Krauth M, Hauswirth A, Derdak S . Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005; 19(8):960-2. DOI: 10.1096/fj.04-1973fje. View

19.

Rebuzzi L, Willmann M, Sonneck K, Gleixner K, Florian S, Kondo R . Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol. 2007; 115(3-4):320-33. DOI: 10.1016/j.vetimm.2006.11.009. View

20.

Onishi I, Nakagawa Y, Murayama T, Hidaka M, Yamamoto K, Abe-Suzuki S . Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia. Pathology. 2014; 46(7):623-9. DOI: 10.1097/PAT.0000000000000180. View